---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-000114"
form_type: "8-K"
ticker: "PROF"
cik: "0001628808"
company_name: "Profound Medical Corp."
filed_at: "2025-01-08T23:59:59+00:00"
generated_at: "2026-05-28T06:47:24.600133+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Profound Medical Q4 revenue up ~105-110% YoY; switches to US GAAP

## Summary
- Preliminary Q4 2024 revenue $4.1-4.2M, YoY growth 105-110%, sequential growth 45-48%.
- Preliminary FY2024 revenue $11.1-11.2M vs $7.2M in FY2023.
- As of Jan 1, 2025, transitioning from IFRS to US GAAP; will file US domestic forms (10-K, 10-Q, 8-K).
- TULSA procedure now reimbursed at Urology APC Level 7 across multiple treatment settings.
- Company to present at JPM 2025 on Jan 16 at 11:15 a.m. PT.

## SEC filing metadata
- accession: 0001171843-25-000114
- form_type: 8-K
- ticker: PROF
- cik: 0001628808
- company_name: Profound Medical Corp.
- filed_at: 2025-01-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1628808/000117184325000114/0001171843-25-000114-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1628808/000117184325000114/f8k_010825.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-000114
- JSON: https://secwatch.observer/filing/0001171843-25-000114.json
- Plain text: https://secwatch.observer/filing/0001171843-25-000114.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.